Introduction

The outbreak of coronavirus disease 2019 (COVID-19) has been recently declared a pandemic by the World Health Organization.1 Cases of positive real-time reverse transcriptase-polymerase chain reaction (RT-PCR) results in patients recovered from coronavirus disease 2019 (COVID-19) have been recently reported.2 However, little is currently known about the prevalence of recurrent positive RT-PCR test results in these patients.

Methods

We examined twenty patients successfully treated for COVID-19 who had a 2-week post-discharge follow-up period who were admitted to the First Affiliated Hospital of Wenzhou Medical University and Wenzhou Central Hospital in Wenzhou, China, between January 25, 2020, and February 26, 2020. Of note, Wenzhou City was the second epicenter of the SARS-CoV-2 outbreak and had the second largest number of cases reported.3

Discharge criteria were as follows: (1) > 3 days of normal body temperature, (2) resolved respiratory symptoms, (3) substantially improved acute exudative lesions on chest computed tomography (CT), and (4) negative RT-PCR test results for both two consecutive salivary tests (with at least 1 day between tests) and one fecal nucleic acid (RNA) test.4 In all these patients, treatment included nebulized α-interferon, as recommended by the Chinese COVID-19 Management Guidance,5 until the aforementioned criteria for hospital discharge were met. Discharged patients were asked to follow strict protocols for self-isolation at designated hotels and away from family or relatives for 2 weeks. This study was approved by our local IRB, waiving informed consent for de-identified data.

Results

At baseline, all SARS-CoV-2 infection–confirmed patients (14 men, 6 women) with age ranging from 23 to 57 years had fever, while 9 also had cough. Their white blood cell (WBC) and lymphocyte counts, expressed as mean ± SD, were 5.02 ± 1.47 × 109/L and 1.31 ± 0.49 × 109/L, respectively. Their chest CT scans showed ground-glass opacities and consolidation that affected varying numbers of lobes with or without bilateral pulmonary involvement.

Seven days after hospital discharge, 3 patients who initially tested negative at discharge developed positive RT-PCR test results. One tested positive by fecal RNA, while two tested positive by both salivary and fecal RNA tests at 1 week of follow-up. Interestingly, all 20 patients returning for the week 2 follow-up tested negative for SARS-CoV-2, irrespective of sampling route. All three cases had improved with no increase in their temperature, and improvement in WBC and lymphocyte counts, as well as their CT scans. Compared with 17 patients with negative RT-PCR results at week 1 follow-up, there were no significant differences in WBC (6.0 vs. 4.9, p = 0.38) or lymphocyte counts (1.9 vs. 1.6, p = 0.25).

Discussion

We found that 3 of 20 patients, 7 days after hospital discharge with negative RT-PCR tests, had a positive RT-PCR test. Two weeks after discharge, all three patients tested negative for viral RNA. Interestingly, there was no difference in symptoms between those who remained negative and those who were positive; all cases experienced steady improvement. Because all discharged patients followed a strict protocol for self-isolation, we believe that the RNA positivity at follow-up is unlikely to be due to reinfection. It remains also uncertain whether recovered COVID-19 patients with positive RT-PCR results are able to transmit the infection to others by close contact. These findings suggest that strict self-isolation protocols and extended follow-up periods might be needed for recovered COVID-19 patients.

Our case series, although the first observational study to longitudinally examine COVID-19 patients, has several important limitations. First, this is a small sample (n = 20), meaning that our results are preliminary and cannot be used to predict the proportion with recurrently positive tests. Secondly, while adherence to self-quarantine in our population is high, it is possible that this represents reinfection rather than persistent infection. Larger and longer-term prospective studies are needed to better understand the outcome of COVID-19.